Mechanism of Action
CGRP Receptor Signaling
cgrp/" class="wiki-internal-link">CGRP activates a heterodimeric receptor complex comprising the calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1). This Gs-coupled receptor increases cAMP and activates PKA in vascular smooth muscle, causing profound vasorelaxation. The intraneuronal component of CGRP signaling activates MAPK pathways and can sensitize trigeminal pain pathways (central sensitization).
Migraine Trigeminovascular Mechanism
During migraine, CGRP is released from trigeminal perivascular fibers into the dural circulation and the systemic circulation. It causes vasodilation of dural and meningeal vessels, activates mast cell degranulation, and sensitizes meningeal nociceptors. The resulting neurogenic inflammation produces the pulsating headache and sensory hypersensitivity characteristic of migraine.
Research Summary
Anti-CGRP Migraine Therapies
FDA Approved (related)Four monoclonal antibodies targeting CGRP (fremanezumab, galcanezumab, eptinezumab) or its receptor (erenumab) are FDA-approved for migraine prevention. Small-molecule CGRP receptor antagonists (gepants: rimegepant, ubrogepant, atogepant) are approved for acute and preventive migraine treatment. These therapies validate CGRP as a central migraine target.
Cardiovascular Effects
PreclinicalCGRP is cardioprotective in ischemia-reperfusion models, reducing infarct size through vasodilation and direct cardiomyocyte protection. CGRP-knockout mice show increased blood pressure and impaired vasodilatory reserve. Concern about anti-CGRP therapies and cardiovascular safety is actively monitored given CGRP role in ischemic protection.
Calculate your Alpha-CGRP dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Migraine trigger model | 1.5 mcg/min IV | 20-min infusion | Intravenous |
| Vasodilation studies | 0.1-10 nM | Single | Organ bath / in vivo |
Anti-CGRP antibodies and gepants are the therapeutic approach. CGRP itself is a research/diagnostic tool.
Interactions
Safety Profile
CGRP itself causes flushing, tachycardia, and headache upon IV infusion. The major clinical concern is the cardiovascular role of CGRP: as a vasodilator in ischemic conditions, prolonged CGRP blockade with long-acting antibodies could theoretically reduce ischemic tolerance. Post-marketing cardiovascular surveillance of anti-CGRP antibodies has not identified significant signals to date.
References
- [1]Amara SG et al. (1982). Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature, 298(5871), 240-244.
- [2]Edvinsson L et al. (2018). CGRP as the target of new migraine therapies, successful translation from bench to clinic. Nature Reviews Neurology, 14(6), 338-350.